Sign in
TerminatedPhase 4

ANti-Oxidant in Variant Angina (ANOVA) Trial

Key facts

Who runs it
Seoul National University Hospital
Where
South Korea1 site in 1 countryChoose a country to see its sites
Trial code
Status
Terminated
Phase
Phase 4
People taking part
320 people enrolled
Started
1 Sept 2014
Ended
1 Jun 2024
Type of study
Interventional, 4 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Vitamin C and Vitamin E
  • Statin
  • Standard medication for variant angina
Record updated
27 April 2026
Why it stopped
The study was terminated early due to slow recruitment and the Principal Investigator's retirement.

Who can take part

Age
30 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 12 criteriaShow less

Who can take part

  • Subject must be at least 30 years of age
  • Subject is able to verbally confirm understandings of risks, benefits and treatment alternatives of receiving the Vitamin C+E or Statin or Dual, and he/she or his/her legally authorized representative provides written informed consent prior to any study related procedure
  • Subject must have symptoms that are consistent with vasospastic angina with planned Coronary angiography and Provocation test

Who cannot take part

  • History of Severe hepatic dysfunction or Rhabdomyolysis due to statin side effect
  • History of Urolithiasis
  • Non-cardiac co-morbid conditions are present with life expectancy <1 year or that may result in protocol non-compliance (per site investigator's medical judgment)
  • Creatinine level ≥ 2.0mg/dL or dependence on dialysis
  • Severe hepatic dysfunction (AST and ALT: 3 times upper normal reference values)
  • Patient who has organic coronary stenosis in main coronary branch at least 50% luminal narrowing after intracoronary nitroglycerin injection
  • Patient who has continuously taken Vitamin C or Vitamin E or Statin within 3months before Admission
  • Active Myopathy or elevated Creatine kinase enzyme level (3 times upper normal reference values)
  • Female of childbearing potential, unless a recent pregnancy test is negative, who possibly plan to become pregnant any time after enrollment into this study

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Purpose Objectives

Read full original descriptionShow less

1. To evaluate the anti-oxidant effect of long-term Vitamin C+E therapy on coronary vasospasm improvement. 2. To evaluate the anti-oxidant effect of long-term statin therapy on coronary vasospasm improvement. 3. To evaluate the effect of long-term Vitamin C+E and statin therapy on regression of atheroma in target coronary vessels via intravascular ultrasound. 4. To find out the role of vascular endothelium in variant angina via evaluating long-term Vitamin C+E and statin therapy on improvement in vascular endothelial function by assessing brachial arterial expansion capability. 5. To find out the role of vascular endothelium in variant angina via evaluating long-term Vitamin C+E and statin therapy on improvement in arterial stiffness by assessing pulse wave velocity(PWV)

The 4 groups in the trial

  • Dual subgroupTreatment being tested

    Standard medication for variant angina plus Vitamin C+E plus Statin Vitamin C and Vitamin E : Ascorbic acid Tablet 1g / Tocopherol Capsule 400IU Statin : Atorvastatin calcium 10mg

    Treatment: Vitamin C and Vitamin E, Statin, and Standard medication for variant angina

  • Statin subgroupTreatment being tested

    Standard medication for variant angina plus Statin Statin : Atorvastatin calcium 10mg

    Treatment: Statin and Standard medication for variant angina

  • Vitamin subgroupTreatment being tested

    Standard medication for variant angina plus Vitamin C+E Vitamin C and Vitamin E : Ascorbic acid Tablet 1g / Tocopherol Capsule 400IU

    Treatment: Vitamin C and Vitamin E and Standard medication for variant angina

  • Control groupExisting treatment, for comparison

    Control subgroup : Standard medication for Variant angina only

    Treatment: Standard medication for variant angina

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Effects of Long-term Vitamin C+E and Statin Therapy on Vasospasm Improvement and Regression of Atheroma in Patients With Variant Angina
Record updated
27 April 2026